Evolus Posts Profit Milestone Amid Strategic Expansion
In Q2 2026, Evolus (NASDAQ:EOLS) reported a significant financial turnaround with adjusted EBITDA of $4.7 million compared to a loss in the same period last year. Global net revenue reached $84.1 million, up 21% from the prior year, driven by toxin sales and new injectable hyaluronic acid gels. The company raised its full-year guidance for both revenue ($330–$337 million) and adjusted gross profit margin (67.0–67.5%). Customer growth was also notable with over 18,600 accounts in the U.S., a reorder rate above 70%, and expansion of its loyalty program to more than 1.5 million members. Evolus is diversifying beyond toxins by launching Estyme HA gels internationally and securing licensing deals for future market entry into Canada, Australia, and New Zealand. It also signed an exclusive U.S. deal with IBSA for Profhilo, a skin quality injectable expected to generate over $100 million in peak annual revenue when launched in 2030.
Topics: ebitda guidance_upgrade profitability revenue_growth